Your browser doesn't support javascript.
loading
The Global Hidradenitis Suppurativa Atlas Methodology: Combining Global Proportions in a Pooled Analysis.
Bouazzi, Dorra; Andersen, Rune K; Vinding, Gabrielle R; Medianfar, Cecilia E; Nielsen, Sabrina M; Saunte, Ditte M L; Chandran, Nisha S; van der Zee, Hessel H; Zouboulis, Christos C; Benhadou, Farida; Villumsen, Bente; Alavi, Afsaneh; Ibekwe, Perpetua U; Hamzavi, Iltefat H; Ingram, John R; Naik, Haley B; Garg, Amit; Boer, Jurr; Christensen, Robin; Jemec, Gregor B E.
Afiliación
  • Bouazzi D; Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.
  • Andersen RK; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Vinding GR; Section for Biostatistics and Evidence-Based Research, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.
  • Medianfar CE; Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.
  • Nielsen SM; Department of Immunology and Microbiology, Skin Immunology Research Center, University of Copenhagen, Copenhagen, Denmark.
  • Saunte DML; Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.
  • Chandran NS; Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.
  • van der Zee HH; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Zouboulis CC; Section for Biostatistics and Evidence-Based Research, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.
  • Benhadou F; Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark.
  • Villumsen B; Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.
  • Alavi A; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Ibekwe PU; European Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
  • Hamzavi IH; Division of Dermatology, Department of Medicine, National University Hospital, Singapore, Singapore.
  • Ingram JR; European Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
  • Naik HB; Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Garg A; European Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
  • Boer J; Departments of Dermatology, Venereology, Allergology and Immunology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, Germany.
  • Christensen R; European Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
  • Jemec GBE; Department of Dermatology, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B.), CUB Hôpital Erasme, Brussels, Belgium.
Dermatology ; 240(3): 369-375, 2024.
Article en En | MEDLINE | ID: mdl-38354718
ABSTRACT

INTRODUCTION:

Data concerning the global burden of hidradenitis suppurativa (HS) are limited. Reported prevalence estimates vary between 0.0003% and 4.1%, and data from various geographical regions are still to be collected. Previously reported prevalences have been limited by the methodological approach and source of data. This has resulted in great heterogeneity as prevalence data from physician-diagnosed cases poorly match those of self-reported apparent HS disease.

METHODS:

The Global Hidradenitis Suppurativa Atlas (GHiSA) introduces an innovative approach to determine the global prevalence of HS. This approach involves using a previously validated questionnaire to screen apparently healthy adults accompanying a patient to a non-dermatological outpatient clinic visit in a hospital or a private/family medicine clinic. The screening questionnaire (i.e., the index test) is combined with a subsequent physician-based in-person validation (i.e., the reference standard) of the participants who screen positive. Approximately ten percent of the screen-negative participants are also clinically assessed to verify the diagnostic precision of the test. The local prevalence (pi) will be estimated from each country that submits the number of patients who are HS positive according to the index test and clinical examination (n), and the corresponding total number of observations (N).

CONCLUSION:

The GHiSA Global Prevalence studies are currently running simultaneously in 58 countries across six continents (Africa, Europe, Australia, North America, South America, and Asia). The goal of the combined global proportion is the generation of a single summary (i.e., proportional meta-analysis), which will be done after a logit transformation and synthesized using a random-effects model. The novel standardization of the Global Prevalence Studies conducted through GHiSA enables direct international comparisons, which were previously not possible due to substantial heterogeneity in past HS prevalence studies.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Salud Global / Hidradenitis Supurativa Tipo de estudio: Risk_factors_studies Límite: Adult / Humans Idioma: En Revista: Dermatology Asunto de la revista: DERMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Dinamarca Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Salud Global / Hidradenitis Supurativa Tipo de estudio: Risk_factors_studies Límite: Adult / Humans Idioma: En Revista: Dermatology Asunto de la revista: DERMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Dinamarca Pais de publicación: Suiza